IL13 and asthma: Therefore, it is plausible to speculate that the coexistence of severe asthma and nasal polyposis could be associated with a higher expression of IL-4 and IL-13 in the airways of patients reporting both these diseases, who would therefore respond to dupilumab with a more relevant decrease in FeNO levels.